In addition to the general blood donation requirements

[zakiyatasnim]

If a patient receiving VV ECMO treatment in combination with mechanical ventilation meets the awake ECMO criteria, we recommend attempting to remove the mechanical airway first unless the patient has ECMO-related complications or the expected time to remove all assist machines is less than 48 hours.
In patients with excessive airway secretions who require frequent artificial suction clearance, who are expected to require long-term mechanical ventilation support, who meet the conditions of PaO2/FiO2>150 mmHg and time>48 h, whose lung imaging improves, and whose mechanical ventilation pressure-related injury has been controlled, ECMO support may be withdrawn. Maintaining ECMO intubation is not recommended.
XI. Treatment of COVID-19 patients with convalescent plasma

Since Behring and Kitasato reported the therapeutic effects of diphtheria antitoxin plasma in 1891, plasma therapy has become an important tool for immunotherapy of acute infectious disease pathogens. This new infectious disease progresses rapidly in severe and critically ill patients. In the early stage, pathogens directly damage target organs and then cause severe immunopathological damage. Passive immune antibodies can effectively and directly neutralize pathogens, which reduces target organ damage and then blocks subsequent immunopathological damage. During multiple global pandemic outbreaks, WHO also emphasized that “convalescent plasma is one of the most recommended potential treatments and has been used in other epidemic outbreaks.” After the COVID-19 outbreak, the initial mortality was quite high due to the lack of specific and effective treatments. Since the mortality rate is an important indicator that the public is concerned about, in order to avoid public panic, clinical treatment that can effectively reduce the mortality rate in critical cases is key. As a provincial hospital in Zhejiang Province, we are responsible for the treatment of patients from Hangzhou and critically ill patients in this province. In our hospital, there are many potential convalescent plasma donors and critically ill patients who need plasma treatment.

1 Plasma collection

and practices, the following details should be noted:

1.1 Donors

At least two weeks after recovery and discharge (nucleic japan number data acid test on lower respiratory tract specimen remains negative for several days). 18≤ Age ≤ 55. Body weight> 50 kg (for men) or> 45 kg (for women). At least one week since last glucocorticoid use. More than two weeks since last blood donation.

1.2 Collection method

Plasmapheresis, 200-400 ml each time (based on medical advice).

1.3 Post-collection examination

In addition to general qualitative analysis and screening for blood-borne diseases, blood samples should be tested for:

SARS-CoV-2 nucleic acid test;
160-fold dilution for qualitative assay to detect SARS-CoV-2-specific IgG and IgM; or 320-fold dilution for qualitative whole antibody detection. If possible, it is recommended to save >3 mL of plasma for virus neutralization experiments.
It should be noted that when comparing the virus neutralization titer and the quantitative luminescent determination of IgG antibodies, we found that the presented detection of specific IgG antibodies against SARS-CoV-2 does not fully demonstrate the actual ability of plasma to neutralize the virus. Therefore, we proposed the virus neutralization test, or the total antibody level at a 320-fold dilution of plasma, as the first option.